Matinas BioPharma Has A Weak Drug Pipeline And Investors...
Matinas BioPharma (MTNB) is one of those rare, no-brainer, diamond in the rough, short ideas. Matinas BioPharma's stock has moved...
Research
(If you're unable to access an article, contact us and we'll email you the full article)
Straight Path Spectrum Value: The Truth Is Revealed In...
Lead attorney for Straight Path's shareholder lawsuit says Straight Path management perpetrated a "years-long fraud". "Use it or lose it"...
Corrections Corp – Delayed Bullish As Private Prisons Are...
While there has been talk of doing away with private prisons for years, investors of private prison operator stocks GEO...
Scientific Games Dominates Gaming Technology – Could Double In...
With Scientific Games large size, the recent CEO change was likely the right choice and investors should buy on current...
Why Relypsa Is Likely A Zero: The Chronic Hyperkalemia...
Hyperkalemia, or high potassium in the blood, is unnecessary to treat unless it's at a severe level. Most medicare and...
Synthesis Energy Is All Talk And No Walk –...
With energy prices low, Synthesis Energy's (SYMX) syngas technology is even more uneconomical than it was when energy prices were...
MannKind Is On Its Way To Bankruptcy – Are...
The full report is published on Seeking Alpha here.
TransEnterix Has Unsellable, Impractical Surgical Bots, Massive Share Dilution...
- We have a price target on TransEnterix (TRXC) of $1.20 by the end of the year. TRXC real goal...
ReWalk Robotics Will “ReWalk” Back To Single Digits
ReWalk’s (RWLK) Veterans Affairs (VA) coverage was expected from the last two earnings calls and already partially priced in. No...
Emerge Energy Services Is Poised To Drop 50% On...
- Emerge Energy Services (EMES) had an atrocious 3rd quarter and is a bankruptcy risk. We have a $2.50 price...
Horsehead Holdings Is A Bankruptcy Risk With Its Dysfunctional...
Horsehead Holdings (ZINC) has risen 100% over the past two weeks from a spike up in zinc prices, which has...
VBL Therapeutics’ VB-111 Cancer Drug Is A Colossal Failure
- VBL Therapeutics (VBLT) put out a PR for its ovarian cancer drug, VB-111 with the word "positive" in the...
Track Record
We have an over 90% success rate
3rd Party Verified:
(click on the stock symbols below to see the reports)
Get Our Latest Reports Delivered To Your Inbox (we will not share your email with anyone)